Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trientine - Protemix

Drug Profile

Trientine - Protemix

Alternative Names: GC 811007; Laszarin; PX 811019

Latest Information Update: 30 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Protemix Corporation
  • Class Ethylenediamines; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus
  • Discontinued Diabetic cardiomyopathy

Most Recent Events

  • 30 Jul 2019 No development reported - Phase-II for Type 2 diabetes mellitus in New Zealand (PO) (ACTRN12612000261819)
  • 20 Jun 2016 Protemix Corporation completes a phase II trial in Non-diabetic Subjects and Type 2 Diabetes Mellitus in New Zealand before February 24, 2012 (ACTRN12612000261819)
  • 24 Feb 2012 Phase-II clinical trials in Type-2 diabetes mellitus in New Zealand (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top